Department of Chemical Engineering, Indian Institute of Science, Bangalore, India.
PLoS One. 2011 Jan 13;6(1):e14531. doi: 10.1371/journal.pone.0014531.
Whether HIV-1 evolution in infected individuals is dominated by deterministic or stochastic effects remains unclear because current estimates of the effective population size of HIV-1 in vivo, N(e), are widely varying. Models assuming HIV-1 evolution to be neutral estimate N(e)10²-10⁴, smaller than the inverse mutation rate of HIV-1 (10⁵), implying the predominance of stochastic forces. In contrast, a model that includes selection estimates N(e)>10⁵, suggesting that deterministic forces would hold sway. The consequent uncertainty in the nature of HIV-1 evolution compromises our ability to describe disease progression and outcomes of therapy. We perform detailed bit-string simulations of viral evolution that consider large genome lengths and incorporate the key evolutionary processes underlying the genomic diversification of HIV-1 in infected individuals, namely, mutation, multiple infections of cells, recombination, selection, and epistatic interactions between multiple loci. Our simulations describe quantitatively the evolution of HIV-1 diversity and divergence in patients. From comparisons of our simulations with patient data, we estimate N(e)10³-10⁴, implying predominantly stochastic evolution. Interestingly, we find that N(e) and the viral generation time are correlated with the disease progression time, presenting a route to a priori prediction of disease progression in patients. Further, we show that the previous estimate of N(e)>10⁵ reduces as the frequencies of multiple infections of cells and recombination assumed increase. Our simulations with N(e)10³-10⁴ may be employed to estimate markers of disease progression and outcomes of therapy that depend on the evolution of viral diversity and divergence.
HIV-1 在感染个体中的进化是由决定性还是随机效应主导尚不清楚,因为目前对 HIV-1 体内有效种群大小(N(e))的估计差异很大。假设 HIV-1 进化为中性的模型估计 N(e)10²-10⁴,小于 HIV-1 的逆突变率(10⁵),这意味着随机力量占主导地位。相比之下,包含选择的模型估计 N(e)>10⁵,表明决定性力量将占主导地位。因此,HIV-1 进化的性质存在不确定性,这影响了我们描述疾病进展和治疗结果的能力。我们对病毒进化进行了详细的位串模拟,考虑了较大的基因组长度,并纳入了感染个体中 HIV-1 基因组多样化的关键进化过程,即突变、细胞的多次感染、重组、选择和多个基因座之间的上位相互作用。我们的模拟定量描述了患者中 HIV-1 多样性和分歧的进化。通过将我们的模拟与患者数据进行比较,我们估计 N(e)10³-10⁴,这意味着主要是随机进化。有趣的是,我们发现 N(e) 和病毒的世代时间与疾病进展时间相关,为患者疾病进展的先验预测提供了一种途径。此外,我们表明,以前估计的 N(e)>10⁵ 随着假设的细胞多次感染和重组频率的增加而降低。我们的 N(e)10³-10⁴ 模拟可以用于估计依赖于病毒多样性和分歧进化的疾病进展和治疗结果的标志物。